Press release
Role of Non-Insulin Therapies in Addressing the Global Diabetes Epidemic Driving Market Acceleration in the Non-Insulin Therapies For Diabetes Industry, 2025
Non-Insulin Therapies For Diabetes
How Large Will the Non-Insulin Therapies For Diabetes Market Size By 2025?
In recent times, the market size for non-insulin treatments for diabetes has experienced significant growth. Predictions indicate an increase from $19.98 billion in 2024 to $21.41 billion in 2025, with a compound annual growth rate (CAGR) of 7.1%. Factors contributing to this growth during the historic period include a rise in diabetes cases, enhanced understanding of diabetes management, increased healthcare spending, lifestyle changes result in higher incidence rates, a boost in diagnoses, increased government efforts toward diabetes care, and a rise in investment in pharmaceutical research and development.
How Big Is the Non-Insulin Therapies For Diabetes Market Size Expected to Grow by 2029?
There is an anticipated strong surge in the non-insulin therapies for diabetes market in the forthcoming years. The market size is projected to expand to $27.9 billion by 2029, with a compound annual growth rate (CAGR) of 6.8%. The expansion during the forecast period is due to factors such as the growing incidence of diabetes, increasing knowledge of diabetes care, the rising use of combination therapies, an increase in the elderly population, the rise in healthcare spending, the broadening scope of telemedicine, and a preference shift towards oral medicines. In the forecasted period, key trends include progress in oral and injectable drugs, advances in drug distribution systems, improvements in oral peptide delivery, the incorporation of telemedicine and digital health solutions, and enhancements in combined therapies.
View the full report here:
https://www.thebusinessresearchcompany.com/report/non-insulin-therapies-for-diabetes-global-market-report
Which Key Market Drivers Powering Non-Insulin Therapies For Diabetes Market Expansion and Growth?
The escalation in diabetes cases is projected to boost the expansion of the non-insulin therapies for diabetes market. Diabetes, a persistent health issue, is distinguished by elevated levels of glucose (sugar) in the blood and happens when the body fails to produce enough insulin, or exploits it incorrectly. The surge in diabetes cases can be attributed to inactive lifestyle, unhealthy eating habits, genetic susceptibility, growing older population, obesity, racial factors, unawareness, restricted healthcare accessibility, and environmental triggers. Non-insulin treatments for diabetes aid in managing the disease by elevating insulin sensitivity, curtailing glucose creation in the liver, magnifying glucose absorption in muscle cells, and ameliorating overall glycemic control. For example, a report presented by The British Diabetic Association, a UK-based diabetes charity in April 2023, unveiled that 4.3 million people in the UK were diagnosed with diabetes. The registry information of 2021-22 saw an escalation of 148,951 cases compared to those of 2020-21. Moreover, over 2.4 million citizens in the UK are at a heightened risk of developing type 2 diabetes. Consequently, the rise in diabetes prevalence is stimulating the growth of the non-insulin therapies for the diabetes market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp
Which Fast-Growing Trends Are Poised to Disrupt the Non-Insulin Therapies For Diabetes Market?
In the non-insulin therapies for diabetes market, leading companies are focusing on the creation of personalized diabetes management systems. These are designed to improve patient outcomes through continuous monitoring, data analytics, and individualized treatment strategies. The aim is to tailor treatment and surveillance to each patient's distinct requirements, utilizing live data and analytics to optimize care and outcomes. For example, US-based pharmaceutical company Eli Lilly and Company launched the Tempo personalized diabetes management platform in November 2022. This platform consists of three core components, namely the Tempo Smart Button, the TempoSmart app, and the Tempo Pen, a prefilled insulin pen. These parts work together to offer personalized advice for adults suffering from diabetes. The innovation aims to support adults with type 1 or type 2 diabetes and their healthcare providers in making knowledgeable, data-dependent treatment choices with Lilly insulins.
What Are the Emerging Segments in the Non-Insulin Therapies For Diabetes Market?
The non-insulin therapies for diabetes market covered in this report is segmented -
1) By Drug Class: Biguanides, Sulfonylureas, Thiazolidinedione's, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Glucagon-like peptide-1 (GLP-1) Analogs, Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral, Intramuscular
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
4) By Application: Monitoring, Diagnosis, Treatment, Other Applications
Subsegments:
1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide
3) By Thiazolidinediones: Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol
5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide, Liraglutide, Dulaglutide, Semaglutide
7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=16494&type=smp
Who Are the Global Leaders in the Non-Insulin Therapies For Diabetes Market?
Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC
Which are the Top Profitable Regional Markets for the Non-Insulin Therapies For Diabetes Industry?
North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16494
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Role of Non-Insulin Therapies in Addressing the Global Diabetes Epidemic Driving Market Acceleration in the Non-Insulin Therapies For Diabetes Industry, 2025 here
News-ID: 4138776 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Diabetes
Major Force in the Diabetes Pen Market 2025: Diabetes Fuels Surge In Demand For …
How Will the Diabetes Pen Market Grow, and What Is the Projected Market Size?
The diabetes pen market is projected to grow from $29.24 billion in 2024 to $31.22 billion in 2025, at a CAGR of 6.8%. Growth is fueled by the rising need for managing diabetes, advancements in diabetes care, and an increasing focus on patient-friendly medication administration tools.
The diabetes pen market is projected to grow strongly, reaching $40.17 billion…
Diabetes Monitoring Devices Market: Regaining Its Glory| Ascensia Diabetes Care, …
The Latest Study Published by HTF MI Research on the "Diabetes Monitoring Devices Market'' evaluates market size, trend and forecast to 2029. The Diabetes Monitoring Devices market study includes significant research data and evidences to be a practical resource document for managers and analysts is, industry experts and other key people to have an easily accessible and self-analysed study to help understand market trends, growth drivers, opportunities and upcoming challenges…
Prevalence of Diabetes Drives Opportunities for Type-2 Diabetes Market
The Type-2 Diabetes Market Analysis, 2023, by MarkNtel Advisors, presents a well-researched, detail-driven, and accurate study for the stakeholders. This analysis entails prominent aspects like trends, & recent developments, drivers, opportunities, challenges, & restraints, among other parameters, influencing the overall industry expansion across different locations. This report comprises data from historic years (2018-21) & the base year (2022) to put together an estimation of the forecast period (2023-28).
According to Type-2 Diabetes Market…
Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face.
Dr. Marlene Merritt (from the Merritt Wellness Center in…
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system.
As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important.
The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end…
Self-Monitoring Blood Glucose Devices Market Study by Advance Application [Type …
The global self-monitoring blood glucose devices market was valued at $7,768 million in 2017 and is projected to reach $10,828 million by 2025 at a CAGR of 4.2% from 2018 to 2025. Monitoring of blood glucose is an essential step in diabetes management. Blood glucose monitoring devices are predominantly used to monitor a patient’s blood glucose level. Self-monitoring blood glucose (SMBG) devices are easy-to-use and enable people to monitor their…
